Cargando…

COVID-19 prophylaxis: half-full or half-empty glass?

Detalles Bibliográficos
Autores principales:	Scarfò, Lydia, Cuneo, Antonio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	by The American Society of Hematology 2023
Materias:	Lymphoid Neoplasia
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9906282/ https://www.ncbi.nlm.nih.gov/pubmed/36633884 http://dx.doi.org/10.1182/blood.2022018858

Ejemplares similares

Is the glass half full or half empty?
por: Abdullah, BJJ, et al.
Publicado: (2007)

Is the glass half full or half empty?
por: Association
Publicado: (2006)

Digital health: Is the glass half-full or half-empty?
por: Lampariello, Riccardo, et al.
Publicado: (2020)

Unicompartmental knee arthroplasty: is the glass half full or half empty?
por: Murray, D. W., et al.
Publicado: (2015)

A randomized trial of alendronate as prophylaxis against loss in bone mineral density following lymphoma treatment
por: Jensen, Paw, et al.
Publicado: (2022)

Testosterone treatment in older men: glass half empty or half full?
por: Nolan, Brendan J, et al.
Publicado: (2017)

High surface IgM levels associate with shorter response to ibrutinib and BTK bypass in patients with CLL
por: Chiodin, Giorgia, et al.
Publicado: (2022)

Immediate COVID-19 treatment in CLL
por: Niemann, Carsten Utoft
Publicado: (2023)

The digital competence of academics in higher education: is the glass half empty or half full?
por: Inamorato dos Santos, Andreia, et al.
Publicado: (2023)

Celebrating World Asthma Day in Brazil: is the glass half full or half empty?
por: Pizzichini, Marcia Margaret Menezes, et al.
Publicado: (2019)

Is the Glass Half Full or Half Empty? How to Reverse the Effect of Glass Elongation on the Volume Poured
por: Caljouw, Simone R., et al.
Publicado: (2014)

COVID-19 in patients with CLL: how can we change the odds?
por: Herishanu, Yair, et al.
Publicado: (2021)

A glass half empty or a glass half full? Addressing the opioid crisis through the lens of COVID-19
por: Strathdee, Steffanie A.
Publicado: (2021)

BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib
por: Bonfiglio, Silvia, et al.
Publicado: (2023)

Multiple COVID-19 vaccine doses in CLL and MBL improve immune responses with progressive and high seroconversion
por: Shen, Yandong, et al.
Publicado: (2022)

ACT-A: half empty or half full?
por: Shisana, Olive, et al.
Publicado: (2022)

Progress in Alzheimer's disease research circa 2013: Is the glass half empty or half full?
por: Galasko, Douglas, et al.
Publicado: (2013)

Tuberculosis preventive treatment in people living with HIV—Is the glass half empty or half full?
por: Oxlade, Olivia, et al.
Publicado: (2021)

Commentary: Thoracic intensive care unit readmissions—glass half full or half empty?
por: Cameron, Robert B.
Publicado: (2022)

Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set
por: Chari, Ajai, et al.
Publicado: (2020)

COVID-specific T's may offset therapeutically endangered B's
por: Hill, LaQuisa C., et al.
Publicado: (2022)

Reconstructing cancer karyotypes from short read data: the half empty and half full glass
por: Eitan, Rami, et al.
Publicado: (2017)

Suitability of administrative claims databases for bariatric surgery research – is the glass half-full or half-empty?
por: Li, Xiaojuan, et al.
Publicado: (2020)

In-Hospital Cardiopulmonary Resuscitation in Patients Receiving Maintenance Dialysis: Glass Half Full or Half Empty?
por: Pun, Patrick H.
Publicado: (2021)

Something not so new for lymphangioleiomyomatosis: is VEGF-D a glass half empty or half full?
por: Amaral, Alexandre Franco, et al.
Publicado: (2022)

Factors associated with long-term outcomes of CD19 CAR T-cell therapy for relapsed/refractory CLL
por: Liang, Emily C., et al.
Publicado: (2023)

Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL
por: Gauthier, Jordan, et al.
Publicado: (2022)

A stem cell epigenome is associated with primary nonresponse to CD19 CAR T cells in pediatric acute lymphoblastic leukemia
por: Masih, Katherine E., et al.
Publicado: (2023)

Low incidence of invasive fungal disease following CD19 chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma
por: Little, Jessica S., et al.
Publicado: (2022)

Risk assessment with low-pass whole-genome sequencing of cell-free DNA before CD19 CAR T-cell therapy for large B-cell lymphoma
por: Cherng, Hua-Jay J., et al.
Publicado: (2022)

Evaluation of 4 prognostic indices in follicular lymphoma treated in first line with immunochemotherapy
por: Rodríguez-Sevilla, Juan Jose, et al.
Publicado: (2022)

Junctional adhesion molecule C expression specifies a CD138(low/neg) multiple myeloma cell population in mice and humans
por: Brandl, Andreas, et al.
Publicado: (2022)

High-risk subtypes of chronic lymphocytic leukemia are detectable as early as 16 years prior to diagnosis
por: Kolijn, P. Martijn, et al.
Publicado: (2022)

Peripheral T-cell lymphoma: molecular profiling recognizes subclasses and identifies prognostic markers
por: Rodríguez, Marta, et al.
Publicado: (2021)

Aspergillosis in the ICU: The glass half-empty?
por: Crawford, S. W.
Publicado: (1996)

Genetic subgroups inform on pathobiology in adult and pediatric Burkitt lymphoma
por: Thomas, Nicole, et al.
Publicado: (2023)

Effectiveness of nirmatrelvir plus ritonavir treatment for patients with chronic lymphocytic leukemia during the Omicron surge
por: Tadmor, Tamar, et al.
Publicado: (2023)

Classification and genetics of pediatric B-other acute lymphoblastic leukemia by targeted RNA sequencing
por: Migita, Natacha Azussa, et al.
Publicado: (2023)

A multicenter analysis of the outcomes with venetoclax in patients with relapsed mantle cell lymphoma
por: Sawalha, Yazeed, et al.
Publicado: (2023)

CDK7 controls E2F- and MYC-driven proliferative and metabolic vulnerabilities in multiple myeloma
por: Yao, Yao, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_10vuj7m340kld6b73s6g6rqr9r